Lonza Group AG (LZAGF.PK)
27 Oct 2016
* Says strong momentum in q3 gives us confidence to specify that core ebit is on track to cross 15% growth line for full-year 2016
* Says Clovis Oncology and Lonza Ltd entered into a manufacturing services agreement - SEC filing
ZURICH Swiss specialty chemicals and pharmaceutical ingredients company Lonza has announced a deal worth up to $300 million to buy InterHealth Nutraceuticals, a developer and manufacturer of nutritional ingredients used in dietary supplements.
* Lonza to spend up to $300 million on health-supplements target
LONDON, July 20 European shares edged up in early trade on Wednesday, with Swiss speciality chemicals and life sciences group Lonza and software firm SAP leading the market higher after reporting solid results.
ZURICH, July 20 Swiss speciality chemicals and life sciences group Lonza raised its guidance for 2016 after reporting the strongest earnings growth in its history during the first six month.
* Raising its guidance for core ebit growth and now expects a double-digit improvement in core ebit for full year of 2016